Aprea Therapeutics, Inc. (APRE) vs Traws Pharma, Inc. (TRAW)

A side-by-side comparison of Aprea Therapeutics, Inc. and Traws Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — APRE vs TRAW

growth of $100 · dividends reinvested · last 7y
APRE -99.8% (-60.0%/yr)TRAW -99.8% (-59.8%/yr)TRAW compounded faster over this window
050100150200250Start $100202120232025$0$0
APRE TRAW

APRE vs TRAW: by the numbers

  • •TRAW is the larger company ($8M vs $8M market cap).
  • •TRAW is profitable (328.67% net margin) while APRE runs a net loss (0.00%).

Metrics side by side

Valuation

MetricAPRETRAW
P/B ratio0.20N/A

Profitability

MetricAPRETRAW
Gross margin0.00%100.00%
Operating margin0.00%-640.68%
Net margin0.00%328.67%
ROE-31.99%N/A
ROIC-33.73%N/A

Growth (annualized)

MetricAPRETRAW
Revenue CAGR (5Y)N/A64.60%
Total return CAGR (5Y)-63.30%-64.14%

Frequently asked

Is APRE or TRAW more profitable?
TRAW runs the higher net margin — APRE at 0.00% versus TRAW at 328.67%.
How have APRE and TRAW total returns compared?
Over the past 5 years, APRE delivered -63.30% and TRAW delivered -64.14% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.